China-based Degron Therapeutics, a specialist in molecular glue-based drugs, has reportedly raised over USD 20 million in a Series A+ financing round last month. The round was supported by investors including the Zhejiang Province “4+1” Biomedical and High-End Equipment Industry Fund, Takeda Ventures, Fontus Capital, Longmen Capital, HaoYue China Healthcare Fund, AIM-HI Accelerator Fund, and returning investor Yuanbio Venture Capital. The proceeds will be used to advance Degron’s innovative pipeline in the molecular glue field.
Advancing the HuR Degradation Pipeline
A key focus of the funding will be to support the clinical study of Degron’s core pipeline asset, a HuR degrader. Patient enrollment for this study is expected to begin this year. HuR, an RNA-binding protein previously considered untreatable, plays a critical role in cancer and inflammation, making it a promising target for Degron’s innovative therapeutic approach.
Future Outlook
With this Series A+ financing, Degron is well-positioned to expand its presence in the molecular glue field. The company’s commitment to advancing its HuR degradation technology underscores its potential to address significant unmet needs in oncology and inflammatory diseases.-Fineline Info & Tech
Leave a Reply